Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Debt Ratio (2019 - 2024)

Seres Therapeutics' Debt Ratio history spans 7 years, with the latest figure at 0.32 for Q2 2024.

  • For Q2 2024, Debt Ratio rose 28.51% year-over-year to 0.32; the TTM value through Jun 2024 reached 0.32, up 28.51%, while the annual FY2023 figure was 0.28, 95.22% up from the prior year.
  • Debt Ratio for Q2 2024 was 0.32 at Seres Therapeutics, up from 0.3 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.32 in Q2 2024 and bottomed at 0.04 in Q3 2021.
  • The 5-year median for Debt Ratio is 0.19 (2023), against an average of 0.17.
  • The largest annual shift saw Debt Ratio crashed 71.41% in 2021 before it skyrocketed 108.87% in 2022.
  • A 5-year view of Debt Ratio shows it stood at 0.07 in 2020, then fell by 3.34% to 0.07 in 2021, then surged by 108.87% to 0.15 in 2022, then soared by 95.22% to 0.28 in 2023, then rose by 12.5% to 0.32 in 2024.
  • Per Business Quant, the three most recent readings for MCRB's Debt Ratio are 0.32 (Q2 2024), 0.3 (Q1 2024), and 0.28 (Q4 2023).